A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 11, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

EDG-7500

Liquid suspension formulation of EDG-7500

DRUG

EDG-7500

Solid oral formulation of EDG-7500

Trial Locations (18)

10016

RECRUITING

NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only), New York

11030

RECRUITING

North Shore University Hospital, Manhasset

19104

RECRUITING

Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine), Philadelphia

22903

RECRUITING

University of Virginia Heart and Vascular Center Fontaine, Charlottesville

28204

RECRUITING

Sanger Heart and Vascular Institute, Charlotte

29425

RECRUITING

Medical University of South Carolina, Charleston

33612

RECRUITING

James A. Haley Veterans' Hospital, Tampa

44195

RECRUITING

Cleveland Clinic, Cleveland

45219

RECRUITING

The Lindner Research Center at Christ Hospital, Cincinnati

64111

RECRUITING

Saint Luke's Hospital of Kansas City, Kansas City

94143

RECRUITING

University of California, San Francisco, San Francisco

94305

RECRUITING

Stanford University Hospital / Stanford Health Care, Stanford

97239

RECRUITING

Oregon Health & Science University (OHSU), Portland

98101

RECRUITING

Virginia Mason Medical Center, Seattle

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Brigham and Womens Hospital, Boston

01805

RECRUITING

Lahey Hospital and Medical Center, Burlington

07960

RECRUITING

Morristown Medical Center (Atlantic Health System), Morristown

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY